Q-omics provides the consensus-scored COA6 profile across patient tissues and cancer cell-line models. COA6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, COA6 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, COA6 RNA expression shows 18,206 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, HNSC, and ACC as cancer lineages where COA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COA6 survival associations across molecular data types. COA6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COA6 RNA expression–survival associations across cancer types. High COA6 expression shows unfavorable associations in LUAD, ACC, UVM, LIHC, HNSC and KICH. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for COA6 RNA expression.
This table summarizes COA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COA6 shows higher tumor expression in HNSC, BLCA, LIHC, LUAD, BRCA and KIRC. The HNSC box plot shows higher COA6 RNA expression in tumor versus normal tissue (log2 FC = +1.575, t-test p < 0.001).
This table shows molecular features associated with COA6 in patient tissues and cancer cell lines. In patient samples, COA6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, COA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
